When your first film is "Hiroshima Mon Amour" or "Eraserhead" it sets an impossibly high bar - but these directors reached it ...

Using the index as a starting point for our own research, we discovered that the companies most suited to deal with the ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on ...

Phosphodiesterase type 5 (PDE5) inhibitors like sildenafil citrate may prevent intrapartum fetal distress. The results contradict an earlier study that indicated benefits with PDE5 inhibitors; further ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors ...